Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 7Phase 1 4Phase NA 3Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 373Neoplasms 323Neoplasm Metastasis 286Leukemia, Myeloid, Acute 277Breast Neoplasms 271Colorectal Neoplasms 238Melanoma 193Ovarian Neoplasms 191Recurrence 183Multiple Myeloma 178Prostatic Neoplasms 156Lung Neoplasms 156Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 114Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 108Brain Neoplasms 105Advanced Solid Tumors 104Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 101Lymphoma 100Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 91

Interventions

Vorinostat 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Extranodal NK-T-Cell × 1 year × Clear all
NCT05377827 2026-05-06

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Washington University School of Medicine

Phase 1 Active not recruiting
6 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Sezary Syndrome, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT00336063 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
18 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07382817 2026-02-27

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms

M.D. Anderson Cancer Center

Phase 1 Recruiting
33 enrolled
Lymphoid

Neoplasms, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

NCT04288726 2025-07-20

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Baylor College of Medicine

Phase 1 Recruiting
18 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡